Biotech Values

[JJM760]

RE: Ariad from the BMO report

We are less optimistic regarding prospects for mTOR inhibitor
ridaforolimus in sarcoma and believe that SUCCEED phase 3
data, while positive, may not be sufficient for FDA approval.
We believe, however, that Merck's commitment to development
beyond sarcoma is signi? cant and should ultimately support approval beyond sarcoma.

Wouldn't you think that the Rida results, while not spectacular, are probably good enough for approval?

Interesting that this guy is essentially giving Aria a $18 target solely on the value of Ponatnib.

Thanks for posting the report.